Skip to main content

Steroids

RheumNow Podcast square

PsA Til Death Do Us Part (1.20.2023)

Jan 20, 2023

Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.

Read Article
2022,wordle

2022 Rheumatology Year in Review

Jan 05, 2023

2022 was a year of recovery, discovery, and some losses.  While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.

Read Article
GCA,woman

In Giant Cell Arteritis, Hospital Admission Is Bad News

MedPage Today
Jan 03, 2023

One-third of patients admitted with giant cell arteritis (GCA) were rehospitalized within 6 months, largely because of complications potentially related to corticosteroid therapy, researchers found in a retrospective cohort study.



Among the cohort of 1,206 patients hospitalized with

Read Article
Lungs ILD

Best of 2022: Approach to ILD in Myositis Syndromes

Dec 19, 2022

Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.

Read Article
GCA,woman

2022 ACR/EULAR Giant Cell Arteritis Classification Criteria

Dec 12, 2022

Giant cell arteritis (GCA) has historically been a clinical diagnosis (visual loss, headache, jaw pain, scalp tenderness, etc) supported by labs and histopathology. Yet the diagnosis and classification of GCA has evolved, so much so that the ACR and EULAR have updated the 1990 Classification

Read Article
Steroid injections worsen knee arthritis Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. https://t.co/pAeU3IzZfx https://t.co/rgJeHM5t62
infusion.biologic.jpg

RECITAL Trial: RTX vs. CTX in CTD-ILD

Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
Knee,injection

Steroid injections worsen knee arthritis

EurekAlert!
Nov 30, 2022

Two studies comparing injections commonly used to relieve the pain of knee osteoarthritis found that corticosteroid injections were associated with the progression of the disease. Results of both studies were presented today at the annual meeting of the Radiological Society of North America (

Read Article
steroids.prednisone.pills_.jpg

Steroids in RA: Friend or foe (or both)?

While have come so far from the days of our patients living on massive doses of steroids, we still have many patients who use steroids for our diseases, with increasing data for toxicity, even in low dose. As someone much smarter than me described them, steroids are our best frenemy.

Read Article
Is #Tofacitinib an option in #PMR poly myalgia rheumatica? RCT of Tofa 5 mg bid vs prednisone 15 mg/d and tapering. Equal results. Needs a phase 3 trial but could be an option if needing to avoid prednisone ex osteoporosis, DM, etc. abst#1107 #ACR22 @RheumNow https://t.co/OgcgslwaB5
ACR Best

ACR Best Abstracts - Day 2

Nov 13, 2022

Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.

Here are the RheumNow faculty selections for #ACRbest abstracts today:

Read Article
Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6
Very cool initiative @Robsonjo4 1. I love patient reported outcomes (PROs) 2. I think we under-appreciate how much steroids affect our patients quality of life Looking forward to seeing this live! #ACR22 #Vasculitis22 @RheumNow https://t.co/1akO1k7VgU
Yr in review #ACR22 @RheumNow 🌟GLORIA 2 yr data: 👉Pred 5mg OD vs PBO >65y/o RA ✅⬇️ disease activity (DAS28 -0.38) ✅⬇️ joint damage (sharp/van der heijde -1.7) ❌ 24% ⬆️ a/e “Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”
Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1
Year in Review #ACR22 GLORIA Low steroid usage: lower DAS28, reduced joint damage BUT 24% increased adverse effects ⁦@RheumNow⁩ https://t.co/vYTAhoQEqr
question-mark-1872634_640.jpg

Do biologics help taper steroids in Adult Still’s Disease?

A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this

Read Article
Short-term intra-articular steroids are effective (unclear- long term benefits) - no increase risk for knee replacement with repeat steroid injx #osteoarthritis @rheumnow #acr22 #acrreview https://t.co/MJHXWePF70
Medicare will cover #DXA testing for these diagnoses ⁦@RheumNow⁩ #acr22 #acrreview https://t.co/keZg0fxyz9
Older woman

Polymyalgia rheumatica: more than just steroids at ACR22

Nov 11, 2022

After decades of having little else proven apart from glucocorticosteroids with which to treat polymyalgia rheumatica (PMR), evidence for steroid-sparing options has grown in recent years, and this crescendo is set to continue at ACR Convergence 2022 in Philadelphia, PA.

Read Article
Target,T2T,bullseye

SLE T2T - Lupus Low Disease Activity State Predicts Outcomes

Nov 03, 2022

Treat-to-target management of SLE has been shown to protect against organ damage and to improve quality of life. Now a prospective study shows that T2T with a goal of lupus low disease activity state and remission has been shown to improve mortality risk.

Read Article
Think about checking Ig levels prior to Rituximab administration. Low IgM was most common after RTX in RA. The following are risk factors for hypogammaglobulinemia: 🧪 Older age 🧪 Use of steroids 🧪 Repeated doses of RTX 🧪 Low Ig at baseline https://t.co/oOjqnmFdYt
bacteria,infection,color

Infection: a Leading Cause of Death in Lupus

Oct 27, 2022

 Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.



Study identified SLE patients from the Spanish Hospital Discharge Database and recorded the frequency of

Read Article
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/mEkaa7Yjt1 https://t.co/BaMYHiG5Pb
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (17% vs 33% non-D2T-RA;p= 0.011) &being on steroids > 6 mos (71% vs 34%, p< 0.001). https://t.co/Ugbr7z7mia https://t.co/TCU7wSfMrS
×